Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies

Partnership Overview:
Eli Lilly and insitro have entered into three strategic agreements to develop novel treatments for metabolic diseases, leveraging insitro's AI and machine learning capabilities combined with Lilly's drug delivery innovations.

Technology Integration:
The collaboration will utilize insitro's AI/ML platform to identify high-value targets for metabolic diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD), and Lilly's GalNAc delivery technology for siRNA therapies.

Agreements Structure:
The first two agreements involve insitro licensing Lilly's GalNAc technology for use with siRNA molecules targeting liver cells. The third agreement focuses on discovering and developing an antibody for a new metabolic disease target, with insitro leading further development and commercialization after candidate selection.

Innovative Approach:
This partnership represents a new paradigm in biotech and pharma alliances, combining multimodal data at scale, machine learning, and advanced drug delivery modalities to address metabolic diseases at their root cause.

Financial and Development Terms:
Insitro retains full global rights to its programs, with Lilly eligible to receive potential milestones and royalties. The collaboration is supported by Lilly's biotech partnership division, Catalyze360-ExploR&D.

Background on Insitro:
Insitro is a machine learning-enabled drug discovery and development company that has raised over $700 million in capital. It uses AI and machine learning to integrate multimodal data from human cohorts and cellular models to identify genetic targets and therapeutic hypotheses.